Skip to main content
. 2023 May 22;15(10):2860. doi: 10.3390/cancers15102860

Figure 3.

Figure 3

EpCAM-CD3 and EpCAM-CD3 human Fc antibodies bind to EpCAM-positive cells and T cells, kill EpCAM-positive target cells, and induce IFN-gamma secretion with T cells. (A) FACS shows binding of EpCAM-CD3 antibody to EpCAM-positive Lovo cells, as well as T cells. (B) RTCA assay demonstrates dose-dependent killing of Lovo target cells by antibody when incubated with T cells. (C) EpCAM-CD3 antibody with T cells induces IFN-gamma secretion against Lovo cells but not against Colo741 cells. (D) FACS shows binding of EpCAM-CD3 human Fc antibody to Lovo and T cells. (E) RTCA assay demonstrates the dose-dependent killing of EpCAM-positive target cells by antibody when incubated with T cells. (F) EpCAM-CD3 hFc antibody with T cells induces IFN-gamma secretion against Lovo cells and not against Colo741 cells. * p < 0.05, Student’s t-test. IFN-gamma secretion increased when the antibody was incubated with T cells against Lovo cells and not against Colo741 cells.